XML 90 R32.htm IDEA: XBRL DOCUMENT v3.3.1.900
Quarterly Financial Data (Unaudited)
 12 Months Ended
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data (Unaudited)
    Quarterly Financial Data (Unaudited)
(In millions, except per share amounts)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Total
Year
2015
 
 
 
 
(a) (b)
 
(c) (d)
 
 
Product revenues, net
$
2,172.3

 
$
2,198.6

 
$
2,391.7

 
$
2,425.9

 
$
9,188.5

Unconsolidated joint business revenues
$
330.6

 
$
337.5

 
$
337.2

 
$
333.9

 
$
1,339.2

Other revenues
$
52.0

 
$
55.6

 
$
49.0

 
$
79.5

 
$
236.1

Total revenues
$
2,555.0

 
$
2,591.6

 
$
2,777.9

 
$
2,839.3

 
$
10,763.8

Gross profit (1)
$
2,242.6

 
$
2,305.5

 
$
2,467.9

 
$
2,507.5

 
$
9,523.4

Net income
$
820.2

 
$
924.8

 
$
1,019.5

 
$
828.7

 
$
3,593.2

Net income attributable to Biogen Inc.
$
822.5

 
$
927.3

 
$
965.6

 
$
831.6

 
$
3,547.0

Net income per share:
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Inc.
$
3.50

 
$
3.94

 
$
4.16

 
$
3.77

 
$
15.38

Diluted earnings per share attributable to Biogen Inc.
$
3.49

 
$
3.93

 
$
4.15

 
$
3.77

 
$
15.34

Weighted-average shares used in calculating:
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Inc.
235.0

 
235.3

 
232.2

 
220.4

 
230.7

Diluted earnings per share attributable to Biogen Inc.
235.6

 
235.7

 
232.6

 
220.8

 
231.2

(In millions, except per share amounts)
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Total
Year
2014
(e)
 
(f) (g)
 
(f)
 
(f)
 
 
Product revenues, net
$
1,742.8

 
$
2,056.3

 
$
2,117.3

 
$
2,287.0

 
$
8,203.4

Unconsolidated joint business revenues
$
296.9

 
$
303.3

 
$
290.7

 
$
304.5

 
$
1,195.4

Other revenues
$
90.1

 
$
61.9

 
$
103.4

 
$
49.2

 
$
304.5

Total revenues
$
2,129.8

 
$
2,421.5

 
$
2,511.4

 
$
2,640.7

 
$
9,703.3

Gross profit (1)
$
1,850.5

 
$
2,129.6

 
$
2,208.8

 
$
2,343.4

 
$
8,532.3

Net income
$
479.7

 
$
723.1

 
$
856.1

 
$
882.6

 
$
2,941.6

Net income attributable to Biogen Inc.
$
480.0

 
$
714.5

 
$
856.9

 
$
883.5

 
$
2,934.8

Net income per share:
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Inc.
$
2.03

 
$
3.02

 
$
3.63

 
$
3.75

 
$
12.42

Diluted earnings per share attributable to Biogen Inc.
$
2.02

 
$
3.01

 
$
3.62

 
$
3.74

 
$
12.37

Weighted-average shares used in calculating:
 
 
 
 
 
 
 
 
 
Basic earnings per share attributable to Biogen Inc.
236.8

 
236.7

 
236.2

 
235.5

 
236.4

Diluted earnings per share attributable to Biogen Inc.
237.8

 
237.4

 
237.0

 
236.3

 
237.2

(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.
(a)
Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of $48.1 million recorded upon entering into the collaboration agreement with AGTC.
(b)
Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a $60.0 million charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.
(c)
Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of $60.0 million recorded upon entering into the collaboration agreement with MTPC.
(d)
Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling $93.4 million.
(e)
Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of $117.7 million recorded upon entering into the collaboration agreement with Eisai.
(f)
Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014. Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.
(g)
Product revenues, net and total revenues for the second quarter of 2014 include the recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with AIFA.